M.D. Anderson Cancer Center: Neoplasms, Plasma Cell trials
The registry lists 35 Neoplasms, Plasma Cell studies with M.D. Anderson Cancer Center as lead sponsor. 2 are open to participants now and 15 have results posted.
Phase 1 17Phase 2 19Phase 3 3No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R MyelomaRecruitingNCT06066359Phase 1/2
- A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple MyelomaRecruitingNCT05055063Phase 1
- Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)TerminatedNCT01927718Not applicableResults posted
- Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide GeneTerminatedNCT01875237Phase 1/2Results posted
- Intervention for Symptom Burden During Maintenance Therapy for Multiple MyelomaCompletedNCT01793051Phase 2Results posted
- Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)CompletedNCT01531998Phase 1/2Results posted
- Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)TerminatedNCT01518153Phase 2Results posted
- A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple MyelomaCompletedNCT01413178Phase 3Results posted
- Prevention of Treatment Induced Neuropathy in Multiple MyelomaCompletedNCT01283997Phase 2Results posted
- High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk MyelomaCompletedNCT01237951Phase 2Results posted
- Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic TransplantTerminatedNCT01174082Phase 2Results posted
- Lenalidomide and High-Dose MelphalanCompletedNCT01079936Phase 1/2Results posted
- Acupuncture for Chemo-Induced Peripheral NeuropathyCompletedNCT00891618Phase 2Results posted
- Busulfan and Fludarabine Followed by Post-transplant CyclophosphamideCompletedNCT00800839Phase 2Results posted
- Methadone, Morphine, or Oxycodone in Treating Pain in Patients With CancerTerminatedNCT00726830Not applicableResults posted
- Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell SupportCompletedNCT00506857Phase 1/2Results posted
- Velcade, Trisenox, Vitamin C and Melphalan for Myeloma PatientsCompletedNCT00469209Phase 1/2Results posted
- Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple MyelomaActive, not recruitingNCT05336383Phase 2
- Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT02579824Phase 1
- Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in MyelomaWithdrawnNCT02114502Phase 2
- Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple MyelomaTerminatedNCT01985477Phase 1
- Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL AmyloidosisTerminatedNCT01807286Phase 1
- Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) PatientsCompletedNCT01440582Phase 1
- Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With MalignanciesWithdrawnNCT01101412Phase 1/2
- TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple MyelomaCompletedNCT01039025Phase 2
- Chemotherapy-Induced Peripheral Neuropathy SurveyWithdrawnNCT01016028
- Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell GraftsWithdrawnNCT00968396Phase 2
- Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic MalignanciesCompletedNCT00521859Phase 1
- Long-Term Follow Up Study for AMD3100 PatientsCompletedNCT00476294
- Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid MalignanciesTerminatedNCT00473551Phase 1
- Bevacizumab and Bortezomib in Patients With Advanced MalignancyCompletedNCT00428545Phase 1
- Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid MalignanciesCompletedNCT00410982Phase 1
- Thalidomide for Multiple MyelomaCompletedNCT00038233Phase 3
- Thalidomide-Dexamethasone for Multiple MyelomaCompletedNCT00038090Phase 2/3
- Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedNCT00005092Phase 1